English: Combination of two brain diagrams in one for comparison. In the left normal brain, in the right brain of a person with Alzheimer’s disease. Diagram of the brain of a person with Alzheimer’s Disease. Diagram of a normal brain. (Photo credit: Wikipedia)
Researchers at Yale School of Medicine have discovered a new drug compound that reverses the brain deficits of Alzheimer’s disease in an animal model.
Their findings are published in the Aug. 5 issue of the journal PLoS Biology.
The compound, TC-2153, inhibits the negative effects of a protein called STtriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory. These cognitive functions are impaired in Alzheimer’s.
“Decreasing STEP levels reversed the effects of Alzheimer’s disease in mice,” said lead author Paul Lombroso, M.D., professor in the Yale Child Study Center and in the Departments of Neurobiology and Psychiatry at Yale School of Medicine.
Lombroso and co-authors studied thousands of small molecules, searching for those that would inhibit STEP activity. Once identified, those STEP-inhibiting compounds were tested in brain cells to examine how effectively they could halt the effects of STEP. They examined the most promising compound in a mouse model of Alzheimer’s disease, and found a reversal of deficits in several cognitive exercises that gauged the animals’ ability to remember previously seen objects.
Read more . . .
The Latest on: Alzheimer’s drug
via Google News
The Latest on: Alzheimer’s drug
- ‘Our hearts beat in unison’: Maryland family learns to cope with dementiaon May 17, 2021 at 6:00 am
Leah DuRant, 75, of Frederick County is one of the 6.2 million Americans who have dementia, a cognitive disorder that impairs one’s ability to remember, think, reason and interact socially, and ...
- Advances in understanding Alzheimer’s provide new hopeon May 17, 2021 at 5:29 am
BY RAYMOND JAMES, D.O., BOCA GRANDE HEALTH CLINIC - While the nation was justly focused on fighting the COVID-19 pandemic, Alzheimer’s Disease and dementia death increased 16 percent according to the ...
- “It’s been a cycle”: Family of Old Dominion University graduate learning to cope with dementiaon May 16, 2021 at 4:29 pm
It’s been a cycle, a gradually progressing disease,” he said. “I look back at the times, it doesn’t feel like that long ago where we were able to have reasonable conversations with her. Now, most of ...
- Blood tests are speeding up drug trials for intractable conditions like Alzheimer'son May 15, 2021 at 7:10 am
Diagnostics that can identify biomarkers of disease in the blood are helping speed drug trials for intractable conditions like Alzheimer's.Why it matters: Blood biomarker diagnostics can help ...
- Alzheimer’s drug designed using Exscientia’s AI technology enters clinicon May 14, 2021 at 1:40 am
An Alzheimer’s disease drug candidate designed using Exscientia’s artificial intelligence (AI) technology has entered Phase I clinical testing, the company announced yesterday. The drug – DSP-0038 – ...
- Foundation For a Better World Honors Alzheimer's Drug Discovery Foundation with Inaugural Claugus Awardon May 13, 2021 at 8:24 am
The Foundation For a Better World (FFBW) recently honored the Alzheimer's Drug Discovery Foundation (ADDF) with the inaugural Claugus Award for its commitment and dedication to Alzheimer's research.
- Exscientia starts trials of AI-designed Alzheimer’s drugon May 13, 2021 at 4:16 am
Exscientia has advanced a drug candidate for Alzheimer's disease into human testing, the third clinical-stage project for the UK specialist in artificial intelligence (AI) based drug discovery ...
- Biogen Hopes Alzheimer’s Drug Mired in Controversy Earns FDA Nodon May 13, 2021 at 2:00 am
Biogen Inc. drug to remove an aberrant amyloid protein from his brain that researchers believe is tied to reduction in memory and brain function in Alzheimer’s patients. Since t ...
- Eli Lilly CEO David Ricks On Alzheimer’s Disease Drugson May 11, 2021 at 12:02 pm
CNBC's Interview With Eli Lilly CEO David Ricks. TYLER MATHISEN: More than six million Americans have Alzheimer's disease, and that number predicted to escalate more than double b ...
- Some Prominent Doctors Continue to Shun Biogen's Alzheimer's Drugon May 9, 2021 at 11:24 am
Biogen (NASDAQ: BIIB) will get a decision on Alzheimer's disease drug aducanumab next month, but a recent op-ed by members of the Food and Drug Administration (FDA) advisory committee that reviewed ...
via Bing News
2 Comments
kennard peterson
do they sell tcp2153 and cost thank you
innovation
Please contact the original author for further information.